Anticounterfeiting package continues its progress
The proposed EU anticounterfeiting measures for medicines continue through the legislative process
There has been a lively debate in the Committees on a number of aspects of the proposals such as unique pack identification, control of traders and control of active pharmaceutical ingredients. The MEPs have also advocated the inclusion of provisions relating to control of internet trading in medicines.
The amendments agreed as a result of the Committee discussions will be the subject of a plenary vote in the European Parliament - probably in June.
Work has also continued in the Council of Ministers working party looking at the proposal and discussions between it and the European Parliament on the proposed amendments will follow.
On the issue of verification of packs of medicinal products at the point of dispensing, the European pharmaceutical trade association, EFPIA, recently published a report on a pilot project on product verification. The project was carried out in the latter part of last year in Sweden in collaboration with the Swedish pharmaceutical retail chain Apoteket. The pilot successfully demonstrated that a product verification system at the point of dispensing, based on a two-dimensional data matrix, is both robust and effective.
The implementation of a robust regulatory framework to address the trade in counterfeit medicines and of an effective system for verifying the authenticity of medicinal products are a priority for all stakeholders and progress on these issues will be reviewed here as it develops.
You may also like
Ingredients
dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations
Read moreThe new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
Manufacturing
Clariant opens first US pharmaceutical-grade PEG excipient manufacturing site in Texas
Clariant has expanded its Clear Lake facility in Texas to produce GMP-compliant pharmaceutical-grade polyethylene glycol excipients, marking its first US-based manufacturing site for the products and strengthening supply chain resilience for North American and Latin American pharma customers